Introduction
The American Congress of Obstetricians and Gynecologists' District II Safe Motherhood Initiative is a regional, multidisciplinary working group focused on reducing severe maternal morbidity and mortality in New York State. This group is comprised of leaders from multiple specialties from community and referral hospitals across New York state. To identify opportunities to reduce maternal VTE, the Subcommittee on Thromboembolism reviewed epidemiology on risk factors for VTE, prophylaxis strategies, evidence supporting specific clinical approaches, and safety guidelines for pharmacologic thromboprophylaxis. This article presents the findings and recommendations of this subcommittee: the obstetric thromboembolism bundle, a comprehensive strategy to reduce obstetric VTE risk distributed to all hospitals in New York State. This article, which reviews the SMI thromboembolism bundle, includes the following:
(1) Assessment tools to determine risk for VTE for the following patient populations: -patients receiving outpatient prenatal care; -patients hospitalized for an antepartum indication; -patients hospitalized for a cesarean or vaginal delivery; and -patients discharged home postpartum.
(2) Protocols and suggested dosing schedules for patients at high-risk for VTE for whom prophylaxis with unfractionated (UFH) or low-molecular-weight heparin are indicated. In comparison, guidelines from the United Kingdom similarly recommend pharmacologic prophylaxis for women with prior venous thromboembolic events or thrombophilias. Additionally, these guidelines recommend prophylaxis for other common risk factors including obesity, maternal age 435 years, smoking, pre-eclampsia, postpartum hemorrhage, and prolonged labor.
2,14 As a result, the UK guidelines recommend more frequent pharmacologic prophylaxis than the U.S. guidelines. 15 In the setting of a comprehensive strategy to reduce VTE, death from this cause in the UK decreased by more than half from 1. 4, 7, 14, 16, 17 Risk assessment recommendations and tools
The Safe Motherhood Initiative recommends that all obstetric patients be assessed for VTE risk at multiple time points in pregnancy including during -presentation for prenatal care; -hospitalization for an antepartum indication; -during a delivery hospitalization (in-house postpartum); and -discharge home from a delivery hospitalization.
VTE prophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) may be based on risk factors or in some situations may be empiric. While the Joint Commission states that all hospitalized patients should receive VTE prophylaxis or have documentation why no prophylaxis was given, this set of recommendations (and Joint Commission quality measure) has generally not been extended to obstetric patients. Given the increasing incidence of VTE and risk factors for events, the SMI recommends that obstetric patients be included in this Joint Commission recommendation. Fig. 1 -Initial assessment during pregnancy.
